Research programme: capsid assembly inhibitors - Arbutus Biopharma

Drug Profile

Research programme: capsid assembly inhibitors - Arbutus Biopharma

Alternative Names: AB 506; ARB-168786; ARB-1820; ARB-880; Core protein inhibitors - Arbutus

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baruch S. Blumberg Institute; Drexel University College of Medicine; Enantigen Therapeutics
  • Developer Arbutus Biopharma
  • Class Hepatoprotectants; Small molecules
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 03 Oct 2017 Arbutus BioPharma intends to file an IND application or equivalent for AB 506 in Hepatitis B (PO) around mid-2018
  • 30 Aug 2016 Arbutus terminates its licence for VLP technology with Kuros
  • 22 Jul 2015 Tekmira intends to file IND applications for hepatitis B therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top